Clinical Programs
The CRDF-004 phase 2 randomized trial for the 1st line treatment of patients with a RAS-mutated metastatic colorectal cancer (mCRC) is designed to generate preliminary safety and efficacy data, and confirm the optimal dose
ENDPOINTS
Primary
- Objective Response Rate: CR + PR
Key Secondary
- Duration of Response
- Progression-Free Survival
Benchmark of Success
- Objective Response Rate ≥65%